Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Joensuu TK - Bisphosphonates are a standard treatment for metastatic bone disease, although agents vary in their potential for renal toxicity. This case report describes the reversal of zoledronic acid-induced renal toxicity by switching treatment to ibandronate in a patient with hormone-refractory prostate cancer and bone metastases.

Related Articles

Phenytoin-facilitated hypoglycaemia in ESRF
British Journal of Renal Medicine, 10/26/09    Relevance Score: 67%

Interindividual variability of drug transporters: Impact on opioid treatment in chronic renal failure
European Journal of Pain, 11/12/09    Relevance Score: 66%

Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects
Journal of Hypertension, 11/20/09    Relevance Score: 65%

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity
Diagnostic Microbiology and Infectious Disease, 11/17/09    Relevance Score: 65%

Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study
Transplant International, 11/06/09    Relevance Score: 65%

Today in Acid-Base...keeping you current

Bone Disease in Medullary Sponge Kidney and Effect of Potassium Citrate Treatment
Clinical Journal of the American Society of Nephrology, 12/14/09

Acid-base regulation of angiotensin receptors in the kidney
Current Opinion in Nephrology and Hypertension, 12/11/09

Activation of p53 Promotes Renal Injury in Acute Aristolochic Acid Nephropathy
Journal of the American Society of Nephrology, 11/23/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address